Skip to main content
Top
Published in: Annals of Surgical Oncology 1/2015

01-01-2015 | Endocrine Tumors

Chasing Calcitonin: Reoperations for Medullary Thyroid Carcinoma

Authors: Courtney J. Balentine, MD, MPH, Herbert Chen, MD

Published in: Annals of Surgical Oncology | Issue 1/2015

Login to get access

Excerpt

In their article, “Biochemical Cure Following Reoperations for Medullary Thyroid Carcinoma: A Meta-Analysis,” Rowland et al.1 provide a very insightful review of the optimal surgical approach for recurrent medullary thyroid cancer. Because no randomized studies exist to guide practicing thyroid surgeons, these authors conducted a thorough meta-analysis of existing studies to determine whether patients with persistently elevated calcitonin after their initial surgery should undergo a targeted procedure removing gross disease or a more extensive compartment-oriented approach. The overall success rate in their study, defined as normalization of calcitonin, was 16.2 %. When classified by surgical technique, a selective approach yielded a biochemical cure rate of 10.5 % (95 % confidence interval [CI], 6.4–14.7), whereas a compartment-oriented approach led to a biochemical cure for 18.6 % (95 % CI, 15.9–21.3). The higher rate of calcitonin normalization with a compartment-oriented surgery was balanced, however, by a higher complication rate that included recurrent laryngeal nerve injury in 5.7 % compared with 1.9 % in the selective surgery group. The compartment-oriented group also experienced an increased incidence of thoracic duct injury, Horner’s syndrome, spinal accessory nerve injury, wound infection, and seromas, but the rate of permanent hypoparathyroidism actually appeared to be higher in the targeted surgery group. The authors note that their data on complications should be interpreted cautiously because their study was not designed to assess this end point. However, it does seem reasonable that more extensive surgery leads to an overall higher complication rate. …
Literature
2.
go back to reference Fialkowski E, DeBenedetti M, and Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg. 2008;32:754–65.PubMedCrossRef Fialkowski E, DeBenedetti M, and Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg. 2008;32:754–65.PubMedCrossRef
3.
go back to reference Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw. 2010;8:549–56.PubMed Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw. 2010;8:549–56.PubMed
4.
go back to reference Moo-Young TA, Traugott AL, Moley JF. Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am. 2009;89:1193–204.PubMedCrossRef Moo-Young TA, Traugott AL, Moley JF. Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am. 2009;89:1193–204.PubMedCrossRef
5.
go back to reference Shepet K, Alhefdhi A, Lai N, et al. Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival. Ann Surg Oncol. 2013;20:1451–5.PubMedCentralPubMedCrossRef Shepet K, Alhefdhi A, Lai N, et al. Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival. Ann Surg Oncol. 2013;20:1451–5.PubMedCentralPubMedCrossRef
6.
go back to reference Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol Oxford. 1998;48:265–73.CrossRef Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol Oxford. 1998;48:265–73.CrossRef
8.
go back to reference Chen H, Sippel RS, O’Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775–83.PubMedCentralPubMedCrossRef Chen H, Sippel RS, O’Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775–83.PubMedCentralPubMedCrossRef
Metadata
Title
Chasing Calcitonin: Reoperations for Medullary Thyroid Carcinoma
Authors
Courtney J. Balentine, MD, MPH
Herbert Chen, MD
Publication date
01-01-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 1/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4109-4

Other articles of this Issue 1/2015

Annals of Surgical Oncology 1/2015 Go to the issue